MedTrace Logo

Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial

NCT04210986 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

Phase I/II randomized, double-blind, placebo-controlled clinical trial to test the safety and efficacy of Fisetin for treating mild to moderate osteoarthritis

Conditions

  • Osteoarthritis, Knee

Interventions

DIETARY_SUPPLEMENT

Fisetin

Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.

DRUG

Placebo oral capsule

Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Office of Naval Research (ONR)

    collaborator FED

  • Steadman Philippon Research Institute

    lead OTHER

Principal Investigators

  • Thomas A Evans, MD · The Steadman Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-06
Primary Completion
2023-01-05
Completion
2023-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04210986 on ClinicalTrials.gov